...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Closure of Patent Ductus Arteriosus With Oral Ibuprofen Suspension in Premature Newborns: A Pilot Study
【24h】

Closure of Patent Ductus Arteriosus With Oral Ibuprofen Suspension in Premature Newborns: A Pilot Study

机译:口服布洛芬悬浮液封闭早产儿动脉导管未闭:一项初步研究

获取原文
           

摘要

Objective. Patent ductus arteriosus (PDA), a common finding among premature infants, is conventionally treated by intravenous indomethacin. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reactions in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to determine whether oral ibuprofen treatment is efficacious and safe in closure of a PDA in premature infants with respiratory distress syndrome.Methods. Twenty-two preterm newborns (gestational age: 27.5 ± 1.75 [range: 23.9–31 weeks]; weight: 979 ± 266 [range: 380-1500 g]) with PDA and respiratory distress syndrome were studied prospectively. They received oral ibuprofen suspension 10 mg/kg/body weight for the first dose, followed at 24-hour intervals by 2 additional doses of 5 mg/kg each, if needed, starting on the second day of life. Echocardiography was performed before treatment and 24 hours after each dose. Every child underwent cranial ultrasonography before and after each ibuprofen dose. The rate of ductal closure, the need for additional treatment, side effects, complications, and the infants’ clinical courses were recorded.Results. Ductal closure was achieved in all newborns except for 1 (95.5%), in whom clinically nonsignificant ductal shunting persisted. No infant required surgical ligation of the ductus. There was no reopening of the ductus after closure had been achieved. Fourteen newborns were treated with 1 dose of ibuprofen, 6 were treated with 2 doses, and the remaining 2 were treated with 3 doses. The survival rate at 1 month was 86.4% (19 of 22). Three (13.6%) infants died from the following causes: 1 who was born at 24 weeks’ gestation with a birth weight of 380 g died as a result of extreme prematurity complications, necrotizing enterocolitis, and low birth weight; 1 died as a result of Candida sepsis; and the third died as a result of Klebsiella sepsis. Intraventricular hemorrhage was observed in 7 infants. The classification was changed from grade 2 to grade 3 in 1 and from grade 0 to grade 1 or higher in 3 others. The rate of survival to discharge was 86.4% (19 of 22). No bronchopulmonary dysplasia was observed in the study group, and there was no case of tendency to bleed. There were no significant differences in the levels of serum creatinine before and after treatment with oral ibuprofen.Conclusions. Oral ibuprofen suspension may be an effective and safe alternative for PDA closure in premature infants with PDA. However, larger comparative studies are warranted.
机译:目的。动脉导管未闭(PDA)是早产婴儿中的常见发现,通常采用静脉消炎痛治疗。最近显示静脉布洛芬对早产儿同样有效,不良反应较少。如果同样有效,那么口服布洛芬对PDA的封闭将比静脉内途径具有多个重要优势。本研究旨在确定口服布洛芬治疗闭合性PDA能否有效治疗呼吸窘迫综合征的早产儿。前瞻性研究了22名患有PDA和呼吸窘迫综合征的早产儿(胎龄:27.5±1.75 [范围:23.9–31周];体重:979±266 [范围:380-1500 g])。他们从第一天开始接受口服布洛芬悬浮液10 mg / kg /体重,然后在生命的第二天开始,每隔24小时再加2剂,每次5 mg / kg。在治疗前和每次给药后24小时进行超声心动图检查。每个儿童在每次服用布洛芬之前和之后都要接受颅骨超声检查。记录下导管闭合的速度,是否需要额外的治疗,副作用,并发症以及婴儿的临床病程。除1例(95.5%)的新生儿(均在临床上无明显导管分流的情况)外,其余所有导管均实现了导管闭合。没有婴儿需要手术结扎导管。闭合后没有再打开导管。 14例新生儿接受1剂量布洛芬治疗,6例接受2剂量治疗,其余2例接受3剂量治疗。 1个月的生存率为86.4%(22中的19)。三名(13.6%)婴儿死于以下原因:1出生于妊娠24周时,出生体重380 g,死于极端早熟并发症,坏死性小肠结肠炎和出生体重低; 1例因念珠菌败血症死亡;第三例因克雷伯菌败血症而死亡。 7例婴儿出现脑室内出血。分类从1级的2级更改为3级,其他3级的级别从0级更改为1级或更高。出院生存率为86.4%(22中的19)。在研究组中未观察到支气管肺发育不良,也没有出血倾向的病例。口服布洛芬治疗前后的血清肌酐水平无显着差异。口服布洛芬混悬液可能是封闭有PDA的早产儿PDA的有效且安全的替代方法。但是,需要进行较大的比较研究。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号